Building a Canadian Translational Bladder Cancer Research Network.
作者信息
Koti Madhuri, Berman David M, Siemens D Robert, Lange Dirk, Wang Edwin, Toren Paul, Eigl Bernhard J, Hardy Céline, Purves Robert, Fradet Vincent, Fradet Yves, Mansure Jose, Kassouf Wassim, Black Peter C
机构信息
Queen's Cancer Research Institute, Kingston, ON, Canada.
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
出版信息
Can Urol Assoc J. 2020 Oct;14(10):E475-E481. doi: 10.5489/cuaj.6887.
Abstract
摘要
相似文献
1
Building a Canadian Translational Bladder Cancer Research Network.
Can Urol Assoc J. 2020 Oct;14(10):E475-E481. doi: 10.5489/cuaj.6887.
2
Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic.
Can Urol Assoc J. 2022 Jun;16(6):E307-E314. doi: 10.5489/cuaj.7810.
3
Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials.
HIV AIDS (Auckl). 2018 Aug 16;10:151-155. doi: 10.2147/HIV.S150107. eCollection 2018.
4
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience.
BJU Int. 2012 Nov;110(9):1324. doi: 10.1111/j.1464-410X.2012.11158.x. Epub 2012 Apr 13.
5
Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
Can Urol Assoc J. 2020 Mar;14(3):E115-E125. doi: 10.5489/cuaj.6378. Epub 2020 Feb 3.
6
Commentary on "Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience." Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W. Department of Surgery (Urology), McGill University, Quebec, Canada: BJU Int 2012;110(9):1317-23 [Epub 2012 Apr 13].
Urol Oncol. 2013 Jul;31(5):717-8. doi: 10.1016/j.urolonc.2013.03.011.
7
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience.
BJU Int. 2012 Nov;110(9):1317-23. doi: 10.1111/j.1464-410X.2012.11133.x. Epub 2012 Apr 13.
8
Building a pan-Canadian primary care sentinel surveillance network: initial development and moving forward.
J Am Board Fam Med. 2009 Jul-Aug;22(4):412-22. doi: 10.3122/jabfm.2009.04.090081.
9
The Canadian Traumatic Brain Injury Research Consortium: Epitomizing Collaborative Research in Canada.
J Neurotrauma. 2018 Aug 15;35(16):1858-1863. doi: 10.1089/neu.2018.5871.
10
Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research.
J Clin Med. 2020 Jul 30;9(8):2433. doi: 10.3390/jcm9082433.
引用本文的文献
1
Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic.
Can Urol Assoc J. 2022 Jun;16(6):E307-E314. doi: 10.5489/cuaj.7810.
本文引用的文献
1
Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
Can Urol Assoc J. 2020 Mar;14(3):E115-E125. doi: 10.5489/cuaj.6378. Epub 2020 Feb 3.
2
Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with Dysfunction.
Clin Cancer Res. 2020 Apr 15;26(8):2065-2079. doi: 10.1158/1078-0432.CCR-19-2230. Epub 2020 Feb 11.
3
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
J Clin Oncol. 2020 Apr 1;38(10):1041-1049. doi: 10.1200/JCO.19.02044. Epub 2020 Feb 7.
4
PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: and Abscopal Effects.
Mol Cancer Ther. 2020 Jan;19(1):211-220. doi: 10.1158/1535-7163.MCT-18-0986. Epub 2019 Sep 18.
5
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
6
DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
J Immunother Cancer. 2019 Jun 7;7(1):148. doi: 10.1186/s40425-019-0619-8.
7
The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance.
Sci Rep. 2019 Apr 23;9(1):6348. doi: 10.1038/s41598-019-42864-w.
8
Epigenetic therapy in immune-oncology.
Nat Rev Cancer. 2019 Mar;19(3):151-161. doi: 10.1038/s41568-019-0109-9.
9
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Cell Death Differ. 2019 Oct;26(10):2100-2114. doi: 10.1038/s41418-019-0278-9. Epub 2019 Jan 28.
10
Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts.
J Pathol. 2019 Apr;247(5):563-573. doi: 10.1002/path.5230. Epub 2019 Feb 20.
Zotero 插件